EGFR and lung adenocarcinoma: Miyata et al. analyzed the long-term survival outcomes and prognostic factors of patients receiving EGFR-TKIs as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma using a multi-institutional database [70].